DataSheet_1_Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors.docx
Carcinoma of unknown primary (CUP) is a clinically aggressive disorder with early tumor dissemination. Identifying molecular traits of CUP can be not only beneficial for a better therapeutic approach but also potentially valuable for patients with general metastatic dissemination.
Patients and MethodsWe retrospectively investigated a total of 35 unique CUP cases. Tumor tissue samples were available in 26 patients, and plasma samples were available in 22 patients. Targeted sequencing was performed with a panel of 416 pan cancer-related genes.
ResultsA genomic landscape of the CUP cohort showed that TP53 mutation was the most frequently observed mutation while MYC amplification was the most common CNV. Aberrant TP53, RTK-RAS, and PI3K signaling pathways were also prevalent, identified in more than half of the cases with tumor tissue. Around 58% of the CUP cases harbored homologous recombinant repair (HRR) pathway gene alterations. The tumor mutational load of CUP patients with altered HRR pathway displayed a significant increase than that of patients with intact HRR. Clinically actionable mutations were identified in eight patients, which may benefit from targeted therapies. Eight patients were treated with platinum-based chemotherapy, showing different responses, HRR, and LOH status.
ConclusionCollectively, our data have provided much-need insights into the treatment options for patients diagnosed with CUP in the era of precision medicine.
History
References
- https://doi.org//10.1016/j.critrevonc.2004.10.002
- https://doi.org//10.1001/jamaoncol.2014.216
- https://doi.org//10.7759/cureus.5552
- https://doi.org//10.1200/JCO.2000.18.17.3101
- https://doi.org//10.1023/A%3A1008369812295
- https://doi.org//10.1634/theoncologist.2009-0112
- https://doi.org//10.1200/JCO.2006.09.3047
- https://doi.org//10.1158/0008-5472.CAN-17-0628
- https://doi.org//10.1158/1078-0432.CCR-17-2310
- https://doi.org//10.3389/fonc.2020.607429
- https://doi.org//10.1016/j.jtho.2021.02.023
- https://doi.org//10.1038/nbt.2203
- https://doi.org//10.1093/nar/gkw520
- https://doi.org//10.1158/1078-0432.CCR-16-3115
- https://doi.org//10.1200/CCI.19.00130
- https://doi.org//10.1093/bioinformatics/btu549
- https://doi.org//10.1002/ctm2.254
- https://doi.org//10.1038/nature10166
- https://doi.org//10.1016/S1470-2045(16)30559-9
- https://doi.org//10.1200/JCO.2019.37.15_suppl.3006
- https://doi.org//10.1016/j.xcrm.2020.100034
- https://doi.org//10.1200/JCO.2010.31.5614
- https://doi.org//10.1016/j.ctrv.2021.102204
- https://doi.org//10.1016/j.cell.2018.03.035
- https://doi.org//10.7150/thno.34070
- https://doi.org//10.1002/cam4.2761
- https://doi.org//10.1186/s13045-021-01089-z
- https://doi.org//10.1016/j.cllc.2011.09.004
- https://doi.org//10.1038/ng.3076
- https://doi.org//10.3389/fonc.2019.00965
- https://doi.org//10.3390/cancers13092125
- https://doi.org//10.3389/fonc.2020.575711
- https://doi.org//10.1016/S1470-2045(20)30445-9
- https://doi.org//10.18632/oncoscience.352
- https://doi.org//10.3389/fonc.2020.00533
- https://doi.org//10.1056/NEJMoa1810858
- https://doi.org//10.1002/onco.13597
- https://doi.org//10.1200/JCO.2020.38.15_suppl.6013
- https://doi.org//10.1007/s11523-021-00841-2
CC BY 4.0